These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21504387)

  • 21. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
    Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
    Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-based therapy in Alzheimer's disease.
    Pul R; Dodel R; Stangel M
    Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational drugs in Alzheimer's disease: current progress.
    Berk C; Paul G; Sabbagh M
    Expert Opin Investig Drugs; 2014 Jun; 23(6):837-46. PubMed ID: 24702504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.
    Crespi GA; Hermans SJ; Parker MW; Miles LA
    Sci Rep; 2015 Apr; 5():9649. PubMed ID: 25880481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond amyloid: the future of therapeutics for Alzheimer's disease.
    Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM
    Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bapineuzumab.
    Kerchner GA; Boxer AL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1121-30. PubMed ID: 20497044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.
    Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S
    Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current progress in beta-amyloid immunotherapy.
    Schenk D; Hagen M; Seubert P
    Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab.
    Roher AE; Maarouf CL; Kokjohn TA; Belden C; Serrano G; Sabbagh MS; Beach TG
    Am J Neurodegener Dis; 2016; 5(4):158-170. PubMed ID: 27725918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease.
    Lannfelt L; Möller C; Basun H; Osswald G; Sehlin D; Satlin A; Logovinsky V; Gellerfors P
    Alzheimers Res Ther; 2014; 6(2):16. PubMed ID: 25031633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.
    Hefti F; Goure WF; Jerecic J; Iverson KS; Walicke PA; Krafft GA
    Trends Pharmacol Sci; 2013 May; 34(5):261-6. PubMed ID: 23582316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.